Adial Pharmaceuticals Inc 's Cash & cash equivalent grew by % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Adial Pharmaceuticals Inc 's Quick Ratio to 5.51, Quick Ratio remained below Adial Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 174 other companies have achieved higher Quick Ratio than Adial Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 0 to 759.

Explain Quick Ratio?
How much Cash & cash equivalents ADIL�s has?
What are ADIL�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ADIL/financial-strength

https://api.csimarket.com/api/v1/companies/ADIL/fundamentals

https://api.csimarket.com/api/v1/companies/ADIL/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

ADIL Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	322.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	376.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	5.51	Subscribe	Subscribe	Subscribe	Subscribe
ADIL's Total Ranking	# 759	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	239.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 175
Healthcare Sector	# 284
Overall Market	# 759

Quick Ratio Statistics
High	Average	Low
34.61	6.72	0.03
(Mar 31 2019)		(Dec 31 2017)

Financial Statements
Adial Pharmaceuticals Inc 's Current Liabilities	$ 5 Millions	Visit ADIL's Balance sheet
Adial Pharmaceuticals Inc 's Cash & cash equivalent	$ 28 Millions	Visit ADIL's Balance sheet
Source of ADIL's Sales		Visit ADIL's Sales by Geography

Cumulative Adial Pharmaceuticals Inc 's Quick Ratio

ADIL's Quick Ratio for the trailling 12 Months

ADIL Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	111.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	124.46 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	4.21	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3617	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	74.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	135.86 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to ADIL Financial Strength Comparisons >> Go to Compare ADIL Quick Ratio to its Competitors

On the trailing twelve months basis ADIL Cash & cash equivalent more than doubled by 376.76 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Adial Pharmaceuticals Inc 's Quick Ratio to 4.21, Quick Ratio remained below ADIL average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 423 other companies have achieved higher Quick Ratio than Adial Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 0 to 3617.

Explain Quick Ratio?
How much Cash & cash equivalents ADIL�s has?
What are ADIL�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 424
Healthcare Sector	# 866
Within the Market	# 3617

trailing twelve months Quick Ratio Statistics
High	Average	Low
19.74	5.92	0.97
(Jun 30 2019)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Anixa Biosciences Inc	15.09	$ 26.330 Millions	$ 1.745 Millions
Siga Technologies Inc	14.99	$ 117.584 Millions	$ 7.845 Millions
Vyne Therapeutics Inc	14.87	$ 22.925 Millions	$ 1.542 Millions
Alto Neuroscience Inc	14.64	$ 243.733 Millions	$ 16.652 Millions
Tenax Therapeutics Inc	14.62	$ 118.000 Millions	$ 8.073 Millions
Jade Biosciences Inc	14.61	$ 461.205 Millions	$ 31.570 Millions
Immunome Inc	14.56	$ 519.996 Millions	$ 35.713 Millions
Sensei Biotherapeutics Inc	14.54	$ 186.441 Millions	$ 12.824 Millions
Cytokinetics Incorporated	14.39	$ 2,610.415 Millions	$ 181.429 Millions
Canton Strategic Holdings Inc	14.18	$ 37.242 Millions	$ 2.626 Millions
An2 Therapeutics Inc	14.04	$ 78.387 Millions	$ 5.585 Millions
Aclaris Therapeutics Inc	13.97	$ 394.443 Millions	$ 28.241 Millions
Pmv Pharmaceuticals Inc	13.85	$ 146.393 Millions	$ 10.568 Millions
Generate Biomedicines Inc	13.76	$ 779.456 Millions	$ 56.636 Millions
Braveheart Bio, Inc.	13.56	$ 122.831 Millions	$ 9.058 Millions
First Tracks Biotherapeutics Inc	13.50	$ 168.018 Millions	$ 12.447 Millions
Arrivent Biopharma inc	13.41	$ 373.401 Millions	$ 27.844 Millions
Cogent Biosciences Inc	13.36	$ 792.300 Millions	$ 59.296 Millions
Aprea Therapeutics Inc	13.33	$ 41.233 Millions	$ 3.092 Millions
Polaryx Therapeutics Inc	13.22	$ 11.542 Millions	$ 0.873 Millions
Monopar Therapeutics Inc	13.14	$ 52.758 Millions	$ 4.016 Millions
Lexicon Pharmaceuticals Inc	12.96	$ 190.610 Millions	$ 14.706 Millions
Korro Bio Inc	12.89	$ 162.805 Millions	$ 12.628 Millions
Atea Pharmaceuticals Inc	12.89	$ 362.382 Millions	$ 28.124 Millions
Oric Pharmaceuticals Inc	12.76	$ 264.761 Millions	$ 20.756 Millions
Diamedica Therapeutics Inc	12.42	$ 81.875 Millions	$ 6.594 Millions
Vtv Therapeutics Inc	12.35	$ 86.643 Millions	$ 7.017 Millions
Theravance Biopharma inc	12.30	$ 378.546 Millions	$ 30.766 Millions
Coya Therapeutics Inc	12.29	$ 43.181 Millions	$ 3.512 Millions
Bridgebio Oncology Therapeutics Inc	12.28	$ 634.167 Millions	$ 51.634 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.